{"qid": "0", "sentence": "<e1> TRPV6 </e1> and <e2> prostate cancer </e2> : cancer growth beyond the prostate correlates with increased TRPV6 Ca2+ channel expression.", "e1": "TRPV6", "e2": "prostate cancer", "ground_truth": "1", "metapaths": [{"pathid": 0, "sim_score": 0.9613069891929626, "stops": "TRPV6 - prostate gland - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 4, "sim_score": 0.921694815158844, "stops": "TRPV6 - TRAF1 - prostate cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 7, "sim_score": 0.9191352128982544, "stops": "TRPV6 - testis - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 3, "sim_score": 0.9110997319221497, "stops": "TRPV6 - urethra - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 6, "sim_score": 0.9015012979507446, "stops": "TRPV6 - bone marrow - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 5, "sim_score": 0.8831165432929993, "stops": "TRPV6 - renal system - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 2, "sim_score": 0.8781909346580505, "stops": "TRPV6 - lymph node - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "1", "sentence": "Dual blockade of <e1> PKA </e1> and NF-\u03baB inhibits H2 relaxin-mediated castrate-resistant growth of <e2> prostate cancer </e2> sublines and induces apoptosis.", "e1": "PKA", "e2": "prostate cancer", "ground_truth": "0", "metapaths": [{"pathid": 0, "sim_score": 0.8031966090202332, "stops": "PKIA - prostate gland - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 3, "sim_score": 0.7577716708183289, "stops": "PKIA - urethra - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 7, "sim_score": 0.7265824675559998, "stops": "PKIA - EPRS - prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 8, "sim_score": 0.700790524482727, "stops": "PKIA - bone marrow - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 1, "sim_score": 0.6893272399902344, "stops": "PKIA - lymph node - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 5, "sim_score": 0.6856058835983276, "stops": "PKIA - NR3C1 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 6, "sim_score": 0.6740274429321289, "stops": "PKIA - BAZ2A - prostate cancer", "reltypes": "COVARIES_GcG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "2", "sentence": "In human <e2> prostate cancer </e2> cells, knockdown of <e1> ILK </e1> expression with siRNA, or inhibition of ILK activity, results in significant inhibition of HIF-1alpha and VEGF expression.", "e1": "ILK", "e2": "prostate cancer", "ground_truth": "0", "metapaths": [{"pathid": 2, "sim_score": 0.8603664636611938, "stops": "ILK - THBS1 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 4, "sim_score": 0.8559911251068115, "stops": "ILK - lymph node - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 1, "sim_score": 0.8498597145080566, "stops": "ILK - SULT1A1 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 6, "sim_score": 0.8267702460289001, "stops": "ILK - MIF - prostate cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 3, "sim_score": 0.8085339665412903, "stops": "ILK - RPN1 - prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 5, "sim_score": 0.8036996126174927, "stops": "ILK - ELAC2 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 0, "sim_score": 0.7705956101417542, "stops": "ILK - STMN1 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "3", "sentence": "Consistently, <e1> CLU </e1> expression was found to be significantly reduced in untreated and hormone-refractory human <e2> prostate carcinomas </e2> .", "e1": "CLU", "e2": "prostate carcinomas", "ground_truth": "0", "metapaths": [{"pathid": 0, "sim_score": 0.645786702632904, "stops": "CLUAP1 - blood - MCM6 - Paroxetine - Prostate carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 10, "sim_score": 0.6355096697807312, "stops": "CLUAP1 - testis - MCM6 - Paroxetine - Prostate carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 7, "sim_score": 0.6086937189102173, "stops": "CLUAP1 - medulla oblongata - MCM6 - Paroxetine - Prostate carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 5, "sim_score": 0.6057204008102417, "stops": "CLUAP1 - head - MCM6 - Paroxetine - Prostate carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 4, "sim_score": 0.5832905769348145, "stops": "CLUAP1 - mammary gland - MCM6 - Paroxetine - Prostate carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 9, "sim_score": 0.5710690021514893, "stops": "CLUAP1 - central nervous system - MCM6 - Paroxetine - Prostate carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 6, "sim_score": 0.5684985518455505, "stops": "CLUAP1 - nervous system - MCM6 - Paroxetine - Prostate carcinoma", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "4", "sentence": "Up-regulation of <e1> c-Jun-NH2-kinase </e1> pathway contributes to the induction of mitochondria-mediated apoptosis by alpha-tocopheryl succinate in human <e2> prostate cancer </e2> cells.", "e1": "c-Jun-NH2-kinase", "e2": "prostate cancer", "ground_truth": "1", "metapaths": [{"pathid": 8, "sim_score": 0.47370368242263794, "stops": "CPOX - seminal vesicle - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 0, "sim_score": 0.43176794052124023, "stops": "CPOX - prostate gland - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 3, "sim_score": 0.4214842617511749, "stops": "CPOX - bone marrow - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 5, "sim_score": 0.4080807864665985, "stops": "CPOX - testis - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 2, "sim_score": 0.39778491854667664, "stops": "CPOX - urethra - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 1, "sim_score": 0.3972214162349701, "stops": "CPOX - lymph node - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 7, "sim_score": 0.39433372020721436, "stops": "CPOX - penis - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "5", "sentence": "In human <e2> prostate cancer </e2> cells, knockdown of ILK expression with siRNA, or inhibition of ILK activity, results in significant inhibition of <e1> HIF-1alpha </e1> and VEGF expression.", "e1": "HIF-1alpha", "e2": "prostate cancer", "ground_truth": "0", "metapaths": [{"pathid": 2, "sim_score": 0.9278048872947693, "stops": "HIF1AN - HIF1A - prostate cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 3, "sim_score": 0.8580653667449951, "stops": "HIF1AN - PAK6 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 1, "sim_score": 0.8498799204826355, "stops": "HIF1AN - SSR2 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 0, "sim_score": 0.8285528421401978, "stops": "HIF1AN - NCOA1 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 5, "sim_score": 0.8272716999053955, "stops": "HIF1AN - MIF - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 6, "sim_score": 0.8134172558784485, "stops": "HIF1AN - NUCB2 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 4, "sim_score": 0.7921817898750305, "stops": "HIF1AN - RPN1 - prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "6", "sentence": "hTERT AS PS-ODN can significantly inhibit telomerase activity by downregulating the <e1> hTERT mRNA </e1> and protein expression, and inhibition of telomerase with hTERT antisense can enhance TNF-alpha-induced apoptosis of <e2> PC3 </e2> cells.", "e1": "hTERT mRNA", "e2": "PC3", "ground_truth": "1", "metapaths": [{"pathid": 7, "sim_score": 0.29629096388816833, "stops": "TERT - breast cancer - Testosterone Propionate - Prostate cancer", "reltypes": "ASSOCIATES_DaG - PALLIATES_CpD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 6, "sim_score": 0.2831999361515045, "stops": "TERT - breast cancer - Testosterone - Prostate cancer", "reltypes": "ASSOCIATES_DaG - PALLIATES_CpD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 5, "sim_score": 0.2713615298271179, "stops": "TERT - HSPA14 - Paroxetine - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 2, "sim_score": 0.2706589996814728, "stops": "TERT - RAN - Paroxetine - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 4, "sim_score": 0.26310065388679504, "stops": "TERT - Ponatinib - Imatinib - Prostate cancer", "reltypes": "UPREGULATES_CuG - RESEMBLES_CrC - CAUSES_CcSE", "nodelabels": "Gene - Compound - Compound - SideEffect"}, {"pathid": 3, "sim_score": 0.21492689847946167, "stops": "TERT - ABL1 - Imatinib - Prostate cancer", "reltypes": "INTERACTS_GiG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 1, "sim_score": 0.17208623886108398, "stops": "TERT - hematologic cancer - Lenalidomide - Prostate cancer metastatic", "reltypes": "ASSOCIATES_DaG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}]}
{"qid": "7", "sentence": "In human <e2> prostate cancer </e2> cells, knockdown of ILK expression with siRNA, or inhibition of ILK activity, results in significant inhibition of HIF-1alpha and <e1> VEGF </e1> expression.", "e1": "VEGF", "e2": "prostate cancer", "ground_truth": "0", "metapaths": [{"pathid": 4, "sim_score": 0.8239759206771851, "stops": "VEGFA - SLC22A4 - Testosterone - Prostate cancer", "reltypes": "REGULATES_GrG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 7, "sim_score": 0.7605377435684204, "stops": "VEGFA - BRCA1 - Ruxolitinib - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 5, "sim_score": 0.7592126131057739, "stops": "VEGFA - RAN - Paroxetine - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 2, "sim_score": 0.750992476940155, "stops": "VEGFA - hematologic cancer - Lenalidomide - Prostate cancer metastatic", "reltypes": "UPREGULATES_DuG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 1, "sim_score": 0.7452940940856934, "stops": "VEGFA - JADE2 - Lenalidomide - Prostate cancer metastatic", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 6, "sim_score": 0.7347749471664429, "stops": "VEGFA - RPS4Y1 - Paroxetine - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 8, "sim_score": 0.7211551666259766, "stops": "VEGFA - BRCA1 - Paroxetine - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "8", "sentence": "hTERT AS PS-ODN can significantly inhibit telomerase activity by downregulating the <e1> hTERT mRNA </e1> and protein expression, and inhibition of telomerase with hTERT antisense can enhance TNF-alpha-induced apoptosis of <e2> PC3 </e2> cells.", "e1": "hTERT mRNA", "e2": "PC3", "ground_truth": "1", "metapaths": [{"pathid": 7, "sim_score": 0.29629096388816833, "stops": "TERT - breast cancer - Testosterone Propionate - Prostate cancer", "reltypes": "ASSOCIATES_DaG - PALLIATES_CpD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 6, "sim_score": 0.2831999361515045, "stops": "TERT - breast cancer - Testosterone - Prostate cancer", "reltypes": "ASSOCIATES_DaG - PALLIATES_CpD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 5, "sim_score": 0.2713615298271179, "stops": "TERT - HSPA14 - Paroxetine - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 2, "sim_score": 0.2706589996814728, "stops": "TERT - RAN - Paroxetine - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 4, "sim_score": 0.26310065388679504, "stops": "TERT - Ponatinib - Imatinib - Prostate cancer", "reltypes": "UPREGULATES_CuG - RESEMBLES_CrC - CAUSES_CcSE", "nodelabels": "Gene - Compound - Compound - SideEffect"}, {"pathid": 3, "sim_score": 0.21492689847946167, "stops": "TERT - ABL1 - Imatinib - Prostate cancer", "reltypes": "INTERACTS_GiG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 1, "sim_score": 0.17208623886108398, "stops": "TERT - hematologic cancer - Lenalidomide - Prostate cancer metastatic", "reltypes": "ASSOCIATES_DaG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}]}
{"qid": "9", "sentence": "Inhibition of the <e1> Akt </e1> , cyclooxygenase-2, and matrix metalloproteinase-9 pathways in combination with androgen deprivation therapy: potential therapeutic approaches for <e2> prostate cancer </e2> .", "e1": "Akt", "e2": "prostate cancer", "ground_truth": "1", "metapaths": [{"pathid": 5, "sim_score": 0.9036551713943481, "stops": "AKT3 - prostate gland - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 3, "sim_score": 0.8712252378463745, "stops": "AKT3 - PENK - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 1, "sim_score": 0.8567640781402588, "stops": "AKT3 - TOP2A - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 4, "sim_score": 0.8275416493415833, "stops": "AKT3 - RPN1 - prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 7, "sim_score": 0.8248195648193359, "stops": "AKT3 - lymph node - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 2, "sim_score": 0.8237173557281494, "stops": "AKT3 - ADAM9 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 0, "sim_score": 0.7752262949943542, "stops": "AKT3 - IGFBP7 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "10", "sentence": "Our results demonstrated that 9-cis RA as a differentiating agent can arrest <e2> prostate cancer </e2> cells in G(1) phase and reduce cell mitosis, and upregulate the expression of <e1> human homeobox gene NKX3.1 </e1> , which is thought to play an important role in prostate differentiation and to act as a tumor suppressor gene in the prostate.", "e1": "human homeobox gene NKX3.1", "e2": "prostate cancer", "ground_truth": "1", "metapaths": [{"pathid": 1, "sim_score": 0.4958125948905945, "stops": "NUMA1 - KCTD5 - prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 5, "sim_score": 0.4795631468296051, "stops": "NUMA1 - HSP90AB1 - prostate cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 4, "sim_score": 0.4523454010486603, "stops": "NUMA1 - CREBBP - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 0, "sim_score": 0.43351906538009644, "stops": "NUMA1 - urethra - prostate cancer", "reltypes": "UPREGULATES_AuG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 6, "sim_score": 0.4325522482395172, "stops": "NUMA1 - EPRS - prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 3, "sim_score": 0.4246498644351959, "stops": "NUMA1 - IRS1 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 2, "sim_score": 0.4009535312652588, "stops": "NUMA1 - TOP2A - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "11", "sentence": "DHT-induced E2F-1 protein and mRNA expressions was also inhibited by BMP-2, suggesting that BMP-2 inhibits DHT-induced growth of <e2> LNCaP </e2> cells through a decrease in <e1> E2F protein </e1> expression and suppression of E2F activity by hypophosphorylation of Rb.", "e1": "E2F protein", "e2": "LNCaP", "ground_truth": "1", "metapaths": [{"pathid": 6, "sim_score": 0.4828677475452423, "stops": "E2F1 - KLF6 - prostate cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 5, "sim_score": 0.47697269916534424, "stops": "E2F1 - CHEK2 - prostate cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 1, "sim_score": 0.45596790313720703, "stops": "E2F1 - BRCA1 - prostate cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 2, "sim_score": 0.43826577067375183, "stops": "E2F1 - GJA1 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 4, "sim_score": 0.41184383630752563, "stops": "E2F1 - SPON2 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 3, "sim_score": 0.40846216678619385, "stops": "E2F1 - CXCL8 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 0, "sim_score": 0.40785321593284607, "stops": "E2F1 - SIRT1 - prostate cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "12", "sentence": "In surgically excised adult human prostate tissues, localized accumulations of <e1> TGF-beta1 </e1> are associated with <e2> prostate cancer </e2> and benign prostatic hyperplasia (BPH).", "e1": "TGF-beta1", "e2": "prostate cancer", "ground_truth": "0", "metapaths": [{"pathid": 7, "sim_score": 0.8698152899742126, "stops": "TGFB1I1 - prostate gland - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 4, "sim_score": 0.8090137839317322, "stops": "TGFB1I1 - testis - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 5, "sim_score": 0.8078938126564026, "stops": "TGFB1I1 - bone marrow - prostate cancer", "reltypes": "DOWNREGULATES_AdG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 0, "sim_score": 0.7866436839103699, "stops": "TGFB1I1 - urethra - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 6, "sim_score": 0.7815408110618591, "stops": "TGFB1I1 - KLF6 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 3, "sim_score": 0.7706061005592346, "stops": "TGFB1I1 - EP300 - prostate cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 2, "sim_score": 0.7657240033149719, "stops": "TGFB1I1 - NR3C1 - prostate cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "13", "sentence": "In human <e2> prostate cancer </e2> cells, knockdown of ILK expression with siRNA, or inhibition of ILK activity, results in significant inhibition of HIF-1alpha and <e1> VEGF </e1> expression.", "e1": "VEGF", "e2": "prostate cancer", "ground_truth": "0", "metapaths": [{"pathid": 4, "sim_score": 0.8239759206771851, "stops": "VEGFA - SLC22A4 - Testosterone - Prostate cancer", "reltypes": "REGULATES_GrG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 7, "sim_score": 0.7605377435684204, "stops": "VEGFA - BRCA1 - Ruxolitinib - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 5, "sim_score": 0.7592126131057739, "stops": "VEGFA - RAN - Paroxetine - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 2, "sim_score": 0.750992476940155, "stops": "VEGFA - hematologic cancer - Lenalidomide - Prostate cancer metastatic", "reltypes": "UPREGULATES_DuG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 1, "sim_score": 0.7452940940856934, "stops": "VEGFA - JADE2 - Lenalidomide - Prostate cancer metastatic", "reltypes": "REGULATES_GrG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 6, "sim_score": 0.7347749471664429, "stops": "VEGFA - RPS4Y1 - Paroxetine - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 8, "sim_score": 0.7211551666259766, "stops": "VEGFA - BRCA1 - Paroxetine - Prostate cancer", "reltypes": "REGULATES_GrG - DOWNREGULATES_CdG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}]}
{"qid": "14", "sentence": "In <e2> PC-3 </e2> cells, adhesion molecule expression, analyzed by immunoblotting, was unaffected by LA, while a down-regulation of <e1> c-met </e1> (up to 28%) was observed after 24 h of treatment but which did not hold up over time (48-144 h).", "e1": "c-met", "e2": "PC-3", "ground_truth": "0", "metapaths": [{"pathid": 3, "sim_score": 0.15239113569259644, "stops": "COMTD1 - THADA - prostate cancer", "reltypes": "COVARIES_GcG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 5, "sim_score": 0.1478935182094574, "stops": "COMTD1 - bone marrow - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 0, "sim_score": 0.13061027228832245, "stops": "COMTD1 - prostate gland - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 1, "sim_score": 0.12616980075836182, "stops": "COMTD1 - lymph node - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 4, "sim_score": 0.10630239546298981, "stops": "COMTD1 - NGFR - prostate cancer", "reltypes": "COVARIES_GcG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 6, "sim_score": 0.08264277130365372, "stops": "COMTD1 - testis - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 2, "sim_score": 0.05888526514172554, "stops": "COMTD1 - urethra - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "15", "sentence": "Transfection of the <e2> PC-3 </e2> prostate cell line with a dominant-negative form of p75( <e1> NTR </e1> ) before DIM treatment significantly rescued cell survival demonstrating a cause and effect relationship between DIM induction of p75(NTR) levels and inhibition of survival.", "e1": "NTR", "e2": "PC-3", "ground_truth": "1", "metapaths": [{"pathid": 4, "sim_score": 0.18938539922237396, "stops": "NKTR - renal system - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 1, "sim_score": 0.18267735838890076, "stops": "NKTR - lymph node - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 0, "sim_score": 0.17122657597064972, "stops": "NKTR - prostate gland - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 6, "sim_score": 0.1502092331647873, "stops": "NKTR - myometrium - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 10, "sim_score": 0.14586229622364044, "stops": "NKTR - lung - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 3, "sim_score": 0.13448397815227509, "stops": "NKTR - urethra - prostate cancer", "reltypes": "UPREGULATES_AuG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 5, "sim_score": 0.13321231305599213, "stops": "NKTR - testis - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "16", "sentence": "DHT-induced <e1> E2F </e1> -1 protein and mRNA expressions was also inhibited by BMP-2, suggesting that BMP-2 inhibits DHT-induced growth of <e2> LNCaP </e2> cells through a decrease in E2F protein expression and suppression of E2F activity by hypophosphorylation of Rb.", "e1": "E2F", "e2": "LNCaP", "ground_truth": "1", "metapaths": [{"pathid": 6, "sim_score": 0.4491364359855652, "stops": "E2F1 - KLF6 - prostate cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 5, "sim_score": 0.4449557662010193, "stops": "E2F1 - CHEK2 - prostate cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 1, "sim_score": 0.40786972641944885, "stops": "E2F1 - BRCA1 - prostate cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 3, "sim_score": 0.3991307318210602, "stops": "E2F1 - CXCL8 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 2, "sim_score": 0.38599419593811035, "stops": "E2F1 - GJA1 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 0, "sim_score": 0.36510422825813293, "stops": "E2F1 - SIRT1 - prostate cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 4, "sim_score": 0.34967994689941406, "stops": "E2F1 - SPON2 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "17", "sentence": "DHT-induced <e1> E2F-1 protein </e1> and mRNA expressions was also inhibited by BMP-2, suggesting that BMP-2 inhibits DHT-induced growth of <e2> LNCaP </e2> cells through a decrease in E2F protein expression and suppression of E2F activity by hypophosphorylation of Rb.", "e1": "E2F-1 protein", "e2": "LNCaP", "ground_truth": "1", "metapaths": [{"pathid": 6, "sim_score": 0.5096415281295776, "stops": "E2F1 - KLF6 - prostate cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 1, "sim_score": 0.5083528161048889, "stops": "E2F1 - BRCA1 - prostate cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 5, "sim_score": 0.5062729120254517, "stops": "E2F1 - CHEK2 - prostate cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 2, "sim_score": 0.48966026306152344, "stops": "E2F1 - GJA1 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 0, "sim_score": 0.4500215947628021, "stops": "E2F1 - SIRT1 - prostate cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 4, "sim_score": 0.43701666593551636, "stops": "E2F1 - SPON2 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 3, "sim_score": 0.43571558594703674, "stops": "E2F1 - CXCL8 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "18", "sentence": "<e1> GRP78 </e1> up-regulation is associated with androgen receptor status, Hsp70-Hsp90 client proteins and castrate-resistant <e2> prostate cancer </e2> .", "e1": "GRP78", "e2": "prostate cancer", "ground_truth": "0", "metapaths": [{"pathid": 6, "sim_score": 0.7711511254310608, "stops": "GPR78 - RPN1 - prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 1, "sim_score": 0.7561368346214294, "stops": "GPR78 - GTF2A2 - prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 0, "sim_score": 0.7513338923454285, "stops": "GPR78 - MIF - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 2, "sim_score": 0.7438767552375793, "stops": "GPR78 - PCNA - prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 5, "sim_score": 0.7400306463241577, "stops": "GPR78 - TYMS - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 4, "sim_score": 0.7295053005218506, "stops": "GPR78 - PRKCQ - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 3, "sim_score": 0.700835108757019, "stops": "GPR78 - HSPE1 - prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "19", "sentence": "3,3'-diindolylmethane induction of p75NTR-dependent cell death via the <e1> p38 mitogen-activated protein kinase </e1> pathway in <e2> prostate cancer </e2> cells.", "e1": "p38 mitogen-activated protein kinase", "e2": "prostate cancer", "ground_truth": "1", "metapaths": [{"pathid": 5, "sim_score": 0.5222029685974121, "stops": "IPO8 - HSP90AB1 - prostate cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 0, "sim_score": 0.517594039440155, "stops": "IPO8 - prostate gland - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 6, "sim_score": 0.5089444518089294, "stops": "IPO8 - RPL23A - prostate cancer", "reltypes": "INTERACTS_GiG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 4, "sim_score": 0.507824182510376, "stops": "IPO8 - renal system - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 2, "sim_score": 0.49112915992736816, "stops": "IPO8 - urethra - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 1, "sim_score": 0.4852346181869507, "stops": "IPO8 - lymph node - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 7, "sim_score": 0.46555912494659424, "stops": "IPO8 - bone marrow - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "20", "sentence": "Dual blockade of PKA and <e1> NF-\u03baB </e1> inhibits H2 relaxin-mediated castrate-resistant growth of <e2> prostate cancer </e2> sublines and induces apoptosis.", "e1": "NF-\u03baB", "e2": "prostate cancer", "ground_truth": "0", "metapaths": [{"pathid": 6, "sim_score": 0.7299486994743347, "stops": "NFIB - CTSD - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 3, "sim_score": 0.7134062051773071, "stops": "NFIB - CBR1 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 1, "sim_score": 0.6945790648460388, "stops": "NFIB - TOP2A - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 4, "sim_score": 0.690878689289093, "stops": "NFIB - RPN1 - prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 0, "sim_score": 0.6887648701667786, "stops": "NFIB - IGFBP7 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 2, "sim_score": 0.6886089444160461, "stops": "NFIB - ICAM1 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 5, "sim_score": 0.682464063167572, "stops": "NFIB - CLIC4 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "21", "sentence": "In <e2> BPH </e2> samples there was a significant correlation between CD38 loss (mean 21% of acini) and <e1> HLA-DR </e1> up-regulation (mean 20%; P &lt; 0.001).", "e1": "HLA-DR", "e2": "BPH", "ground_truth": "0", "metapaths": [{"pathid": 2, "sim_score": 0.5070487260818481, "stops": "HLA-DRA - AHR - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 4, "sim_score": 0.4861610233783722, "stops": "HLA-DRA - CCND1 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 1, "sim_score": 0.4844585657119751, "stops": "HLA-DRA - WRN - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 0, "sim_score": 0.47394025325775146, "stops": "HLA-DRA - RPS19 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 6, "sim_score": 0.4578406810760498, "stops": "HLA-DRA - CHEK2 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 5, "sim_score": 0.4438556134700775, "stops": "HLA-DRA - CD82 - prostate cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 3, "sim_score": 0.41114407777786255, "stops": "HLA-DRA - NR3C1 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "22", "sentence": "The absence of <e1> CD38 </e1> and presence of HLA-DR expression in prostatic epithelium is consistent in <e2> BPH </e2> and tissue surrounding tumour, and strongly related to gland atrophy.", "e1": "CD38", "e2": "BPH", "ground_truth": "0", "metapaths": [{"pathid": 1, "sim_score": 0.6040843725204468, "stops": "CD38 - CD9 - prostate cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 2, "sim_score": 0.5667391419410706, "stops": "CD38 - bone marrow - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 0, "sim_score": 0.5596376061439514, "stops": "CD38 - lymph node - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 5, "sim_score": 0.527117133140564, "stops": "CD38 - hematologic cancer - Imatinib - Prostate cancer", "reltypes": "ASSOCIATES_DaG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 4, "sim_score": 0.490649938583374, "stops": "CD38 - LCK - Imatinib - Prostate cancer", "reltypes": "INTERACTS_GiG - BINDS_CbG - CAUSES_CcSE", "nodelabels": "Gene - Gene - Compound - SideEffect"}, {"pathid": 3, "sim_score": 0.4769423305988312, "stops": "CD38 - hematologic cancer - Lenalidomide - Prostate cancer metastatic", "reltypes": "ASSOCIATES_DaG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 6, "sim_score": 0.42792728543281555, "stops": "CD38 - hematologic cancer - Ruxolitinib - Prostate cancer", "reltypes": "ASSOCIATES_DaG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}]}
{"qid": "23", "sentence": "Our findings demonstrate the efficacy of LA in upregulating E-cadherin, \u03b2- and <e1> \u03b3-catenin </e1> in <e2> LNCaP </e2> cells.", "e1": "\u03b3-catenin", "e2": "LNCaP", "ground_truth": "0", "metapaths": [{"pathid": 0, "sim_score": 0.19223545491695404, "stops": "TP73 - PFDN5 - prostate cancer", "reltypes": "INTERACTS_GiG - DOWNREGULATES_DdG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 2, "sim_score": 0.19035471975803375, "stops": "TP73 - EP300 - prostate cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 4, "sim_score": 0.18117095530033112, "stops": "TP73 - testis - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 5, "sim_score": 0.17981480062007904, "stops": "TP73 - MYC - prostate cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 3, "sim_score": 0.157849982380867, "stops": "TP73 - CREBBP - prostate cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 6, "sim_score": 0.1515718251466751, "stops": "TP73 - TP53 - prostate cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 1, "sim_score": 0.14417105913162231, "stops": "TP73 - SIRT1 - prostate cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "24", "sentence": "Transfection of the <e2> PC-3 </e2> prostate cell line with a dominant-negative form of <e1> p75 </e1> (NTR) before DIM treatment significantly rescued cell survival demonstrating a cause and effect relationship between DIM induction of p75(NTR) levels and inhibition of survival.", "e1": "p75", "e2": "PC-3", "ground_truth": "1", "metapaths": [{"pathid": 6, "sim_score": 0.34729814529418945, "stops": "GPR75-ASB3 - HSP90AA1 - QARS - prostate cancer", "reltypes": "INTERACTS_GiG - INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Gene - Disease"}, {"pathid": 1, "sim_score": 0.3274049162864685, "stops": "GPR75-ASB3 - HSP90AA1 - TOP2A - prostate cancer", "reltypes": "INTERACTS_GiG - REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Gene - Disease"}, {"pathid": 0, "sim_score": 0.30202144384384155, "stops": "GPR75-ASB3 - HSP90AA1 - RALBP1 - prostate cancer", "reltypes": "INTERACTS_GiG - INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Gene - Disease"}, {"pathid": 2, "sim_score": 0.28303205966949463, "stops": "GPR75-ASB3 - CUL5 - TOP2A - prostate cancer", "reltypes": "INTERACTS_GiG - INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Gene - Disease"}, {"pathid": 3, "sim_score": 0.25593599677085876, "stops": "GPR75-ASB3 - CUL5 - UBE2F - prostate cancer", "reltypes": "INTERACTS_GiG - INTERACTS_GiG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Gene - Disease"}, {"pathid": 5, "sim_score": 0.25506752729415894, "stops": "GPR75-ASB3 - DCUN1D1 - PTEN - prostate cancer", "reltypes": "INTERACTS_GiG - REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Gene - Disease"}, {"pathid": 4, "sim_score": 0.22167028486728668, "stops": "GPR75-ASB3 - DCUN1D1 - UBE2F - prostate cancer", "reltypes": "INTERACTS_GiG - INTERACTS_GiG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Gene - Disease"}]}
{"qid": "25", "sentence": "Moreover, 76% of all CD38-negative acini in <e2> BPH </e2> had <e1> HLA-DR </e1> up-regulation in the same prostate epithelial cells, predominantly in atrophic and cystic glands, and in cells with retained secretions (74%).", "e1": "HLA-DR", "e2": "BPH", "ground_truth": "0", "metapaths": [{"pathid": 2, "sim_score": 0.5070487260818481, "stops": "HLA-DRA - AHR - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 4, "sim_score": 0.4861610233783722, "stops": "HLA-DRA - CCND1 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 1, "sim_score": 0.4844585657119751, "stops": "HLA-DRA - WRN - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 0, "sim_score": 0.47394025325775146, "stops": "HLA-DRA - RPS19 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 6, "sim_score": 0.4578406810760498, "stops": "HLA-DRA - CHEK2 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 5, "sim_score": 0.4438556134700775, "stops": "HLA-DRA - CD82 - prostate cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 3, "sim_score": 0.41114407777786255, "stops": "HLA-DRA - NR3C1 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "26", "sentence": "These data suggest that blocking <e1> TSPO </e1> function in tumor cells induces cell death and denotes a survival role for TSPO in <e2> prostate cancer </e2> and provides the first evidence for the use of benzodiazepines in prostate cancer therapeutics.", "e1": "TSPO", "e2": "prostate cancer", "ground_truth": "1", "metapaths": [{"pathid": 0, "sim_score": 0.962326169013977, "stops": "TSPO - prostate gland - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 10, "sim_score": 0.9418655037879944, "stops": "TSPO - epithelium - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 8, "sim_score": 0.9233107566833496, "stops": "TSPO - testis - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 3, "sim_score": 0.9095457792282104, "stops": "TSPO - urethra - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 6, "sim_score": 0.9031264781951904, "stops": "TSPO - bone marrow - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 2, "sim_score": 0.8906479477882385, "stops": "TSPO - lymph node - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 5, "sim_score": 0.8859738707542419, "stops": "TSPO - renal system - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}]}
{"qid": "27", "sentence": "Inhibition of <e1> ILK </e1> activity also inhibits <e2> prostate tumor </e2> angiogenesis and suppresses tumor growth.", "e1": "ILK", "e2": "prostate tumor", "ground_truth": "1", "metapaths": [{"pathid": 4, "sim_score": 0.8241040706634521, "stops": "ILK - lymph node - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 2, "sim_score": 0.8205082416534424, "stops": "ILK - THBS1 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 1, "sim_score": 0.8142358660697937, "stops": "ILK - SULT1A1 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 6, "sim_score": 0.800058901309967, "stops": "ILK - MIF - prostate cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 3, "sim_score": 0.7616035342216492, "stops": "ILK - RPN1 - prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 5, "sim_score": 0.7604488134384155, "stops": "ILK - ELAC2 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 0, "sim_score": 0.7328304648399353, "stops": "ILK - STMN1 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "28", "sentence": "Constitutive activation of MAPK/ERK inhibits <e2> prostate cancer </e2> cell proliferation through upregulation of <e1> BRCA2 </e1> .", "e1": "BRCA2", "e2": "prostate cancer", "ground_truth": "1", "metapaths": [{"pathid": 9, "sim_score": 0.8252063989639282, "stops": "BRCA2 - testis - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 5, "sim_score": 0.8222857117652893, "stops": "BRCA2 - lymph node - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 15, "sim_score": 0.8162360191345215, "stops": "BRCA2 - endocrine gland - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 1, "sim_score": 0.8017611503601074, "stops": "BRCA2 - bone marrow - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 8, "sim_score": 0.7987890243530273, "stops": "BRCA2 - female reproductive system - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 6, "sim_score": 0.7520201802253723, "stops": "BRCA2 - adrenal gland - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 13, "sim_score": 0.7399622797966003, "stops": "BRCA2 - endometrium - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "29", "sentence": "Inhibition of <e1> telomerase </e1> with human telomerase reverse transcriptase antisense increases the sensitivity of tumor necrosis factor-alpha-induced apoptosis in <e2> prostate cancer </e2> cells.", "e1": "telomerase", "e2": "prostate cancer", "ground_truth": "1", "metapaths": [{"pathid": 2, "sim_score": 0.6357100605964661, "stops": "EOMES - TGFB1 - prostate cancer", "reltypes": "COVARIES_GcG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 3, "sim_score": 0.6013696789741516, "stops": "EOMES - bone marrow - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 0, "sim_score": 0.5799924731254578, "stops": "EOMES - lymph node - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 6, "sim_score": 0.5273956060409546, "stops": "EOMES - hematologic cancer - Imatinib - Prostate cancer", "reltypes": "ASSOCIATES_DaG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 5, "sim_score": 0.511840283870697, "stops": "EOMES - hematologic cancer - Lenalidomide - Prostate cancer metastatic", "reltypes": "ASSOCIATES_DaG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 8, "sim_score": 0.48493024706840515, "stops": "EOMES - multiple sclerosis - Pregabalin - Prostate cancer", "reltypes": "ASSOCIATES_DaG - PALLIATES_CpD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}, {"pathid": 7, "sim_score": 0.47867295145988464, "stops": "EOMES - hematologic cancer - Ruxolitinib - Prostate cancer", "reltypes": "ASSOCIATES_DaG - TREATS_CtD - CAUSES_CcSE", "nodelabels": "Gene - Disease - Compound - SideEffect"}]}
{"qid": "30", "sentence": "Immunohistochemical analysis of tissue microarrays in combination with multispectral quantitative imaging comparing <e1> RLN2 </e1> levels in patients with benign prostatic hyperplasia ( <e2> BPH </e2> ), prostatic intraepithelial neoplasia, and CaP determined that RLN2 is significantly upregulated in CaP vs BPH (p = 0.002).", "e1": "RLN2", "e2": "BPH", "ground_truth": "0", "metapaths": [{"pathid": 6, "sim_score": 0.42663145065307617, "stops": "RLN2 - head - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 2, "sim_score": 0.41190704703330994, "stops": "RLN2 - prostate gland - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 7, "sim_score": 0.40387189388275146, "stops": "RLN2 - endocrine gland - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 3, "sim_score": 0.3427368700504303, "stops": "RLN2 - brain - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 5, "sim_score": 0.3234879672527313, "stops": "RLN2 - nervous system - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 1, "sim_score": 0.3068341016769409, "stops": "RLN2 - central nervous system - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 8, "sim_score": 0.2936165928840637, "stops": "RLN2 - central nervous system - JADE2 - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "31", "sentence": "In human <e2> prostate cancer </e2> cells, knockdown of <e1> ILK </e1> expression with siRNA, or inhibition of ILK activity, results in significant inhibition of HIF-1alpha and VEGF expression.", "e1": "ILK", "e2": "prostate cancer", "ground_truth": "0", "metapaths": [{"pathid": 2, "sim_score": 0.8603664636611938, "stops": "ILK - THBS1 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 4, "sim_score": 0.8559911251068115, "stops": "ILK - lymph node - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 1, "sim_score": 0.8498597145080566, "stops": "ILK - SULT1A1 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 6, "sim_score": 0.8267702460289001, "stops": "ILK - MIF - prostate cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 3, "sim_score": 0.8085339665412903, "stops": "ILK - RPN1 - prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 5, "sim_score": 0.8036996126174927, "stops": "ILK - ELAC2 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 0, "sim_score": 0.7705956101417542, "stops": "ILK - STMN1 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}]}
{"qid": "32", "sentence": "Overexpressing <e1> PKIB </e1> in <e2> prostate cancer </e2> promotes its aggressiveness by linking between PKA and Akt pathways.", "e1": "PKIB", "e2": "prostate cancer", "ground_truth": "1", "metapaths": [{"pathid": 0, "sim_score": 0.9606142640113831, "stops": "PKIB - prostate gland - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 2, "sim_score": 0.9252827763557434, "stops": "PKIB - PRKACB - prostate cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 1, "sim_score": 0.9083420038223267, "stops": "PKIB - testis - prostate cancer", "reltypes": "EXPRESSES_AeG - LOCALIZES_DlA", "nodelabels": "Gene - Anatomy - Disease"}, {"pathid": 10, "sim_score": 0.7755491137504578, "stops": "PKIB - liver - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 7, "sim_score": 0.7721921801567078, "stops": "PKIB - midbrain - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - DOWNREGULATES_AdG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 9, "sim_score": 0.7455365657806396, "stops": "PKIB - central nervous system - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}, {"pathid": 3, "sim_score": 0.7275492548942566, "stops": "PKIB - medulla oblongata - SQRDL - Lenalidomide - Prostate cancer metastatic", "reltypes": "EXPRESSES_AeG - EXPRESSES_AeG - UPREGULATES_CuG - CAUSES_CcSE", "nodelabels": "Gene - Anatomy - Gene - Compound - SideEffect"}]}
{"qid": "33", "sentence": "In human <e2> prostate cancer </e2> cells, knockdown of ILK expression with siRNA, or inhibition of ILK activity, results in significant inhibition of <e1> HIF-1alpha </e1> and VEGF expression.", "e1": "HIF-1alpha", "e2": "prostate cancer", "ground_truth": "0", "metapaths": [{"pathid": 2, "sim_score": 0.9278048872947693, "stops": "HIF1AN - HIF1A - prostate cancer", "reltypes": "INTERACTS_GiG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 3, "sim_score": 0.8580653667449951, "stops": "HIF1AN - PAK6 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 1, "sim_score": 0.8498799204826355, "stops": "HIF1AN - SSR2 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 0, "sim_score": 0.8285528421401978, "stops": "HIF1AN - NCOA1 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 5, "sim_score": 0.8272716999053955, "stops": "HIF1AN - MIF - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 6, "sim_score": 0.8134172558784485, "stops": "HIF1AN - NUCB2 - prostate cancer", "reltypes": "REGULATES_GrG - ASSOCIATES_DaG", "nodelabels": "Gene - Gene - Disease"}, {"pathid": 4, "sim_score": 0.7921817898750305, "stops": "HIF1AN - RPN1 - prostate cancer", "reltypes": "REGULATES_GrG - UPREGULATES_DuG", "nodelabels": "Gene - Gene - Disease"}]}
